drugset
drugset / Trial / NCT01377922

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

NCT01377922 ↗

Phase 3 Completed 38 enrolled Catalyst Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).

Timeline

Start
2011-06
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Amifampridine Small molecule — —

Indications

Lambert-Eaton myasthenic syndrome